Larkberget

Larkberget P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Larkberget (LARK.ST) as of Oct 20, 2026 is -3.81. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -1.63 — a change of 134.34% (lower).

P/CF

-3.81

YoY

134.34%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Larkberget is 2025 -3.81 . P/CF (Price-to-Cash-Flow Ratio) of Larkberget was 2024 -1.63 . It decreases by 134.34% lower compared to the previous year.

The Larkberget P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
214.02 SEK
Jan 1, 2019
-2.25 SEK
Jan 1, 2020
-1.27 SEK
Jan 1, 2021
2.20 SEK
Jan 1, 2022
-2.92 SEK
Jan 1, 2023
-1.59 SEK
Jan 1, 2024
-1.63 SEK
Jan 1, 2025
-3.81 SEK
The Larkberget P/CF history
YEARP/CFYoY
-3.81+134.34%
-1.63+2.03%
-1.59-45.46%
-2.92-232.70%
2.20-273.39%
-1.27-43.66%
-2.25-101.05%
214.02-4,286.09%
-5.11-7.55%
-5.53-28.64%
-7.75-90.13%
-78.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Larkberget Stock analysis

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Larkberget stock

P/CF (Price-to-Cash-Flow Ratio) of Larkberget is -3.81 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Larkberget changed from -1.63 to -3.81, representing a 134.34% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Larkberget since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Larkberget

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Larkberget